Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.

Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, Kristeleit H, Farrugia D, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Godeaux O, López-Fauqued M, Salaun B, Heineman TC, Oostvogels L; Zoster-028 Study Group.

Cancer. 2019 Apr 15;125(8):1301-1312. doi: 10.1002/cncr.31909. Epub 2019 Feb 1.

2.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.

N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.

3.

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E.

J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824. Epub 2016 Jan 25.

PMID:
26811519
4.

Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology.

Calles A, Rubio-Viqueira B, Hidalgo M.

Curr Protoc Pharmacol. 2013 Jun;Chapter 14:Unit 14.26. doi: 10.1002/0471141755.ph1426s61.

PMID:
23744711
5.

The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.

Conde E, Angulo B, Izquierdo E, Muñoz L, Suárez-Gauthier A, Plaza C, Dominguez N, Torres M, Madrigal L, Rubio-Viqueira B, Belda-Iniesta C, Hidalgo M, López-Ríos F.

Histopathology. 2013 Mar;62(4):609-16. doi: 10.1111/his.12037. Epub 2013 Feb 5.

6.

A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.

Angulo B, Conde E, Suárez-Gauthier A, Plaza C, Martínez R, Redondo P, Izquierdo E, Rubio-Viqueira B, Paz-Ares L, Hidalgo M, López-Ríos F.

PLoS One. 2012;7(8):e43842. doi: 10.1371/journal.pone.0043842. Epub 2012 Aug 27.

7.

Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M.

Neoplasia. 2012 Aug;14(8):690-701.

8.

Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M.

Clin Cancer Res. 2011 Sep 1;17(17):5793-800. doi: 10.1158/1078-0432.CCR-11-0341. Epub 2011 Jul 8.

9.

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer.

Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D.

Mol Cancer Ther. 2011 Aug;10(8):1311-6. doi: 10.1158/1535-7163.MCT-11-0233. Epub 2011 Jun 14.

10.

Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.

Gallmeier E, Hermann PC, Mueller MT, Machado JG, Ziesch A, De Toni EN, Palagyi A, Eisen C, Ellwart JW, Rivera J, Rubio-Viqueira B, Hidalgo M, Bunz F, Göke B, Heeschen C.

Stem Cells. 2011 Mar;29(3):418-29. doi: 10.1002/stem.595.

11.

The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung.

Conde E, Angulo B, Redondo P, Toldos O, García-García E, Suárez-Gauthier A, Rubio-Viqueira B, Marrón C, García-Luján R, Sánchez-Céspedes M, López-Encuentra A, Paz-Ares L, López-Ríos F.

PLoS One. 2010 Aug 17;5(8):e12209. doi: 10.1371/journal.pone.0012209.

12.

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M.

Br J Cancer. 2010 Aug 24;103(5):649-55. doi: 10.1038/sj.bjc.6605819. Epub 2010 Jul 27.

13.

A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.

Jimeno A, Rubio-Viqueira B, Rajeshkumar NV, Chan A, Solomon A, Hidalgo M.

Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.

14.

Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, Jauch KW, Hidalgo M, Heeschen C.

Gastroenterology. 2009 Sep;137(3):1102-13. doi: 10.1053/j.gastro.2009.05.053. Epub 2009 Jun 6.

PMID:
19501590
15.

Characterizing DNA methylation patterns in pancreatic cancer genome.

Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M.

Mol Oncol. 2009 Dec;3(5-6):425-38. doi: 10.1016/j.molonc.2009.03.004. Epub 2009 Apr 22.

16.

Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.

Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM.

J Clin Oncol. 2009 Apr 10;27(11):1893-8. doi: 10.1200/JCO.2008.19.2930. Epub 2009 Mar 9.

PMID:
19273704
17.

A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.

Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García E, López-Ríos F, Matsui W, Maitra A, Hidalgo M.

Mol Cancer Ther. 2009 Feb;8(2):310-4. doi: 10.1158/1535-7163.MCT-08-0924. Epub 2009 Jan 27.

18.

New scaffolds for the design of selective estrogen receptor modulators.

Martín-Santamaría S, Rodríguez JJ, de Pascual-Teresa S, Gordon S, Bengtsson M, Garrido-Laguna I, Rubio-Viqueira B, López-Casas PP, Hidalgo M, de Pascual-Teresa B, Ramos A.

Org Biomol Chem. 2008 Oct 7;6(19):3486-96. doi: 10.1039/b806918b. Epub 2008 Aug 4.

PMID:
19082149
19.

Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.

Rubio-Viqueira B, Hidalgo M.

Clin Pharmacol Ther. 2009 Feb;85(2):217-21. doi: 10.1038/clpt.2008.200. Epub 2008 Nov 12. Review. No abstract available.

PMID:
19005462
20.

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.

Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA, Hidalgo M.

Cancer Res. 2008 Apr 15;68(8):2841-9. doi: 10.1158/0008-5472.CAN-07-5200.

21.

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.

Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald V, Maitra A, Iacobuzio-Donahue C, Hidalgo M.

Mol Cancer Ther. 2007 Mar;6(3):1079-88.

22.

Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.

Rubio-Viqueira B, Mezzadra H, Nielsen ME, Jimeno A, Zhang X, Iacobuzio-Donahue C, Maitra A, Hidalgo M, Altiok S.

Mol Cancer Ther. 2007 Feb;6(2):515-23.

23.

Assessment of celecoxib pharmacodynamics in pancreatic cancer.

Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M.

Mol Cancer Ther. 2006 Dec;5(12):3240-7.

24.

Targeting mTOR for cancer treatment.

Rubio-Viqueira B, Hidalgo M.

Adv Exp Med Biol. 2006;587:309-27. Review.

PMID:
17163174
25.

An in vivo platform for translational drug development in pancreatic cancer.

Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M.

Clin Cancer Res. 2006 Aug 1;12(15):4652-61.

26.

Targeting mTOR for cancer treatment.

Rubio-Viqueira B, Hidalgo M.

Curr Opin Investig Drugs. 2006 Jun;7(6):501-12. Review.

PMID:
16784020
27.

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.

Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA.

Clin Cancer Res. 2006 Apr 15;12(8):2492-7. Erratum in: Clin Cancer Res. 2007 Jul 15;13(14):4313. Rubio-Viquiera, Belen [corrected to Rubio-Viqueira, Belen].

28.

Current status of mammalian target of rapamycin inhibitors in lung cancer.

Gómez-Martín C, Rubio-Viqueira B, Hidalgo M.

Clin Lung Cancer. 2005 Sep;7 Suppl 1:S13-8. Review.

PMID:
16159415
29.

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.

Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M.

Cancer Res. 2005 Apr 15;65(8):3003-10.

Supplemental Content

Loading ...
Support Center